title: Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.
abstract: OBJECTIVE
  Results of the ICON4/AGO-OVAR-2.2 trial suggest that a platinum/taxane combination provides a survival benefit in relapsed, platinum-sensitive ovarian cancer compared to platinum alone. The optimal specific combination has yet to be determined. The current study evaluates weekly docetaxel and carboplatin in this setting.
  
  
  METHODS
  Using a prospective phase II design, patients received weekly docetaxel (35 mg/m2) and carboplatin (AUC=2) administered days 1, 8, and 15 of a 28-day cycle. Initial treatment with a platinum-based regimen was required, with a treatment-free interval of at least 3 months. Patients could have received one prior regimen for recurrence. Biologically evaluable disease (CA-125) could be followed only if measurable disease was not present. Quality of life analysis utilized the FACT-O and FACT/GOG-Ntx scales.
  
  
  RESULTS
  Thirty-six patients enrolled in the trial over 29 months. The majority had ovarian cancer (89%) and stage III/IV (97%) disease, with a median initial disease-free interval of 12 months. Most subjects were treated for first recurrence (81%) and had measurable disease (58%). The overall response rate was 67% (PR=52%, CR=15%), with 22% stable disease. Grade 3/4 neutropenia was common (48%) while serious anemia and thrombocytopenia were not. Neuropathy was generally mild and manageable. Carboplatin hypersensitivity led to 11 subjects coming off trial (31%). Diphenhydramine premedication produced a nonsignificant decrease in reaction rate. There was no detectable difference in quality of life due to therapy.
  
  
  CONCLUSIONS
  The weekly regimen of carboplatin and docetaxel has a good response rate with an acceptable toxicity profile.
authors.affiliation: Division of Gynecologic Oncology, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, and Regional Cancer Center at Oconomowoc/Waukesha Memorial Hospitals, WI, USA. dmkushner@wisc.edu
authors.forename: David M
authors.initials: DM
authors.lastname: Kushner
authors.forename: Joseph P
authors.initials: JP
authors.lastname: Connor
authors.forename: Federico
authors.initials: F
authors.lastname: Sanchez
authors.forename: Michael
authors.initials: M
authors.lastname: Volk
authors.forename: Julian C
authors.initials: JC
authors.lastname: Schink
authors.forename: Howard H
authors.initials: HH
authors.lastname: Bailey
authors.forename: Linda S
authors.initials: LS
authors.lastname: Harris
authors.forename: Sarah L
authors.initials: SL
authors.lastname: Stewart
authors.forename: Jason
authors.initials: J
authors.lastname: Fine
authors.forename: Ellen M
authors.initials: EM
authors.lastname: Hartenbach
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin